Racemic Ketamine: Balanced Dissociative Profile.
Racemic ketamine (a 50:50 mix of the R- and S-enantiomers) offers a balanced dissociative and psychedelic profile that’s widely used in glutamatergic neuropharmacology. Compared with single-enantiomer formulations, racemic ketamine provides a broader receptor interaction pattern (NMDA antagonism with downstream AMPA/mTOR signaling), making it valuable for preclinical and translational studies into mood, cognition, and neuroplasticity.
Key Features
-
Balanced enantiomer mix: Combines the pronounced sensory/dissociative character often associated with S-ketamine and the investigational, potentially longer-tail mood signals explored with R-ketamine.
-
Robust research utility: Suitable for head-to-head assays, receptor binding work, and circuit-level investigations.
-
High-purity sourcing: Consistent lots and documentation (COA, batch traceability) for reproducibility.
-
Versatile study designs: Supports in-vitro and in-vivo models examining perception, memory, stress response, and synaptic remodeling.
Applications (Research Use Only)
-
Glutamatergic pathway research (NMDA/AMPA, mTOR, plasticity)
-
Comparative enantiomer studies (racemic vs. R- and S-ketamine)
-
Circuit-level work on dissociation, time perception, and body awareness
-
Preclinical models in neuropsychiatry and cognition
Harm Reduction & Safety (Non-numeric, No Clinical Guidance)
Outside regulated clinical settings, ketamine exposure can cause dissociation, impaired coordination, time distortion, increased heart rate/blood pressure, nausea, and—when patterns of heavy/frequent use occur—urinary/bladder complications. Very high intranasal exposures may approach anesthesia-like territory for some individuals and require a safe, supervised environment. Avoid polysubstance combinations (especially depressants such as alcohol, opioids, benzodiazepines). Do not drive or operate machinery under effects. If adverse symptoms become severe (e.g., unresponsiveness, breathing problems), seek emergency help immediately.
.
| Dose | Effects |
|---|---|
| 20 mg | Very mild uplift, slight buzz, almost no dissociation. |
| 40 mg | Noticeable dissociation, light visual distortions, music/sound more immersive, mild wobbliness. |
| 60 mg | Stronger dissociation, partial K-hole possible, pronounced visual and cognitive alterations. |
| 80 mg | Moderate dissociation, internal focus, time distortion, body awareness reduced, can still communicate if needed. |
| 100 mg | Strong dissociation, likely K-hole for many, time distortion, minimal motor control. |
| 120 mg | Deep K-hole experience, intense internal visions, significant loss of body awareness. |
| 150 mg | Full K-hole likely, profound internal experience, functional mobility lost, high nausea risk. |
| 200 mg | Near-anesthesia, complete loss of awareness of surroundings, strong nausea and disorientation risk. |







Reviews
There are no reviews yet.